ARTICLE | Finance
Venture Report: Five biotechs raise nearly $800M in two-day flurry
Plus: New capital for CytoReason, Truvian and Renalys
July 18, 2024 11:14 PM UTC
Five biotechs raised nearly $800 million in venture rounds over the course of two days this week — and the majority were growth financings from crossover investors.
Cardiovascular play Cardurion Pharmaceuticals Inc. brought in the largest of the rounds, announcing Wednesday it had raised $260 million in a series B led by Ascenta Capital. According to BioCentury’s BCIQ database, the financing was the seventh largest disclosed venture round so far this year...
BCIQ Company Profiles